Bristol’s Growth Plan Faces First Test In 2022
New Drugs Hit $1bn Mark In 2021, But First Revlimid Generics Launch This Year
Zeposia, Reblozyl, Breyanzi and Abecma turned BMS’s new product portfolio into a blockbuster revenue stream last year to help fill the $3.5bn gap created by Revlimid and Abraxane generics.
You may also be interested in...
Bristol’s New Products Meet Early Launch Expectations
Sales rose significantly for Reblozyl and for Abecma and Breyanzi, despite manufacturing challenges for the two cell therapies. Newly approved Opdualag and Camzyos are off to encouraging starts.
The Next Big Patent Cliff Is Coming, And Time Is Running Out To Pad The Fall
Blockbusters like Stelara, Eliquis, Prolia and Ibrance are poised to lose US exclusivity over the next five years; pressure is mounting for industry to replenish the portfolio with the next high-growth brands.
BMS Wins Competition For Novel Checkpoint Inhibitors With Relatlimab Approval
The LAG-3 antibody relatlimab, with Opdivo in the fixed-dose combo Opdualag and a $27,389-per-dose price, is the first approved in a new class of checkpoint inhibitors since the anti-PD-1/PD-L1s.